Psychiatry Research
Volume 170, Issue 2 , Pages 161-167, 30 December 2009

Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach☆

  • Ilya A. Lipkovich

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Lipkovich is to be contacted at Tel.: +1 317 651 6095; fax: +1 317 276 7100. Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
    • ,
  • Walter Deberdt

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • ,
  • John G. Csernansky

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, USA
    • Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    • ,
  • Peter Buckley

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
    • ,
  • Joseph Peuskens

      Affiliations

    • The Catholic University of Leuven, University Centre St Jozef, Kortenberg, Belgium
    • ,
  • Sara Kollack-Walker

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Lipkovich is to be contacted at Tel.: +1 317 651 6095; fax: +1 317 276 7100. Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
    • ,
  • Matthew Rotelli

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • ,
  • John P. Houston

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 28 September 2007; received in revised form 13 February 2008; accepted 19 September 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This work has been previously presented at scientific meetings including the American Society for Experimental NeuroTherapeutics Annual Conference in Washington, DC, March 3–5, 2005; Society of Biological Psychiatry Annual Conference in Atlanta, GA, May 19–21, 2005; and New Clinical Drug Evaluation Unit Annual Conference in Boca Raton, FL, June 6–9, 2005.

PII: S0165-1781(08)00311-9

doi:10.1016/j.psychres.2008.09.004

Psychiatry Research
Volume 170, Issue 2 , Pages 161-167, 30 December 2009

Article Tools

* Image Usage & Resolution